{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:16:46Z","timestamp":1790482606091,"version":"4.1.0"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2018,3,8]],"date-time":"2018-03-08T00:00:00Z","timestamp":1520467200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["316655"],"award-info":[{"award-number":["316655"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["MA 929\/11-1"],"award-info":[{"award-number":["MA 929\/11-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Medical Research Council Fellowship","award":["G:0900466"],"award-info":[{"award-number":["G:0900466"]}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI051355"],"award-info":[{"award-number":["R01AI051355"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,5,25]]},"DOI":"10.1093\/infdis\/jiy102","type":"journal-article","created":{"date-parts":[[2018,2,23]],"date-time":"2018-02-23T20:10:25Z","timestamp":1519416625000},"page":"1907-1917","source":"Crossref","is-referenced-by-count":64,"title":["Epitope-Specific Humoral Responses to Human Cytomegalovirus Glycoprotein-B Vaccine With MF59: Anti-AD2 Levels Correlate With Protection From Viremia"],"prefix":"10.1093","volume":"217","author":[{"given":"Ilona","family":"Baraniak","sequence":"first","affiliation":[{"name":"Institute for Immunity and Transplantation, University College London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Kropff","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Klinische und Molekulare Virologie, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary R","family":"McLean","sequence":"additional","affiliation":[{"name":"Cellular and Molecular Immunology Research Centre, London Metropolitan University, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Pichon","sequence":"additional","affiliation":[{"name":"Clinical Development, Sanofi Pasteur, Marcy l\u2019Etoile, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Piras-Douce","sequence":"additional","affiliation":[{"name":"Clinical Development, Sanofi Pasteur, Marcy l\u2019Etoile, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard S B","family":"Milne","sequence":"additional","affiliation":[{"name":"Institute for Immunity and Transplantation, University College London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colette","family":"Smith","sequence":"additional","affiliation":[{"name":"Research Department of Infection and Population Health, University College London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Mach","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Klinische und Molekulare Virologie, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul D","family":"Griffiths","sequence":"additional","affiliation":[{"name":"Institute for Immunity and Transplantation, University College London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew B","family":"Reeves","sequence":"additional","affiliation":[{"name":"Institute for Immunity and Transplantation, University College London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,3,8]]},"reference":[{"key":"key\n\t\t\t\t20180626074929_CIT0001","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1086\/508173","article-title":"Seroprevalence of cytomegalovirus infection in the United States, 1988-1994","volume":"43","author":"Staras","year":"2006","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180626074929_CIT0002","doi-asserted-by":"crossref","first-page":"1121.e9","DOI":"10.1016\/j.cmi.2015.06.009","article-title":"Patients with refractory CMV infection following allo-HSCT are at high risk for CMV disease and non-relapse mortality","volume":"21","author":"Liu","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t20180626074929_CIT0003","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/j.transproceed.2015.04.056","article-title":"Evaluation of infectious complications in the first year after kidney transplantation","volume":"47","author":"Yalci","year":"2015","journal-title":"Transplant Proc"},{"key":"key\n\t\t\t\t20180626074929_CIT0004","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/tid.12398","article-title":"Risk factors and prognostic scale for cytomegalovirus (CMV) infection in CMV-seropositive patients after allogeneic hematopoietic cell transplantation","volume":"17","author":"Cohen","year":"2015","journal-title":"Transpl Infect Dis"},{"key":"key\n\t\t\t\t20180626074929_CIT0005","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/path.4437","article-title":"The pathogenesis of human cytomegalovirus","volume":"235","author":"Griffiths","year":"2015","journal-title":"J Pathol"},{"key":"key\n\t\t\t\t20180626074929_CIT0006","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1128\/CMR.00023-08","article-title":"Neuropathogenesis of congenital cytomegalovirus infection: disease mechanisms and prospects for intervention","volume":"22","author":"Cheeran","year":"2009","journal-title":"Clin Microbiol Rev"},{"key":"key\n\t\t\t\t20180626074929_CIT0007","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1056\/NEJM199203053261003","article-title":"The outcome of congenital cytomegalovirus infection in relation to maternal antibody status","volume":"326","author":"Fowler","year":"1992","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180626074929_CIT0008","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0002-9394(99)00415-8","article-title":"Ocular lesions associated with HIV infection in India: a series of 100 consecutive patients evaluated at a referral center","volume":"129","author":"Biswas","year":"2000","journal-title":"Am J Ophthalmol"},{"key":"key\n\t\t\t\t20180626074929_CIT0009","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jcv.2013.05.002","article-title":"Cytomegalovirus viraemia in HIV exposed and infected infants: prevalence and clinical utility for diagnosing CMV pneumonia","volume":"58","author":"Hsiao","year":"2013","journal-title":"J Clin Virol"},{"key":"key\n\t\t\t\t20180626074929_CIT0010","volume-title":"Vaccines for the 21st century: A tool for decisionmaking","author":"Institute of Medicine Committee to Study Priorities for Vaccine Development;","year":"2000"},{"key":"key\n\t\t\t\t20180626074929_CIT0011","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1128\/IAI.12.3.521-527.1975","article-title":"Candidate cytomegalovirus strain for human vaccination","volume":"12","author":"Plotkin","year":"1975","journal-title":"Infect Immun"},{"key":"key\n\t\t\t\t20180626074929_CIT0012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0140-6736(74)92997-3","article-title":"Development of a vaccine against mental retardation caused by cytomegalovirus infection in utero","volume":"1","author":"Elek","year":"1974","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180626074929_CIT0013","doi-asserted-by":"crossref","first-page":"6980","DOI":"10.1016\/j.vaccine.2012.09.056","article-title":"The next generation recombinant human cytomegalovirus vaccine candidates-beyond gB","volume":"30","author":"Lilja","year":"2012","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20180626074929_CIT0014","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S2055-6640(20)30872-4","article-title":"Cytomegalovirus vaccines under clinical development","volume":"2","author":"Schleiss","year":"2016","journal-title":"J Virus Erad"},{"key":"key\n\t\t\t\t20180626074929_CIT0015","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1006\/viro.1993.1575","article-title":"Glycoprotein B of human cytomegalovirus promotes virion penetration into cells, transmission of infection from cell to cell, and fusion of infected cells","volume":"197","author":"Navarro","year":"1993","journal-title":"Virology"},{"key":"key\n\t\t\t\t20180626074929_CIT0016","doi-asserted-by":"crossref","first-page":"e00332","DOI":"10.1128\/mBio.00332-13","article-title":"Human cytomegalovirus (HCMV) glycoprotein gB promotes virus entry in trans acting as the viral fusion protein rather than as a receptor-binding protein","volume":"4","author":"Wille","year":"2013","journal-title":"MBio"},{"key":"key\n\t\t\t\t20180626074929_CIT0017","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1128\/JVI.01251-08","article-title":"Human cytomegalovirus glycoprotein B is required for virus entry and cell-to-cell spread but not for virion attachment, assembly, or egress","volume":"83","author":"Isaacson","year":"2009","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20180626074929_CIT0018","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1128\/JVI.64.3.1079-1085.1990","article-title":"Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response","volume":"64","author":"Britt","year":"1990","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20180626074929_CIT0019","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.coviro.2012.01.001","article-title":"Human cytomegalovirus entry into cells","volume":"2","author":"Vanarsdall","year":"2012","journal-title":"Curr Opin Virol"},{"key":"key\n\t\t\t\t20180626074929_CIT0020","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1086\/382751","article-title":"Protection against congenital cytomegalovirus infection and disease in guinea pigs, conferred by a purified recombinant glycoprotein B vaccine","volume":"189","author":"Schleiss","year":"2004","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180626074929_CIT0021","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1086\/315060","article-title":"Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine","volume":"180","author":"Frey","year":"1999","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180626074929_CIT0022","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/00006454-200202000-00009","article-title":"Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers","volume":"21","author":"Mitchell","year":"2002","journal-title":"Pediatr Infect Dis J"},{"key":"key\n\t\t\t\t20180626074929_CIT0023","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1093\/infdis\/jir138","article-title":"Glycoprotein B vaccine is capable of boosting both antibody and CD4 T-cell responses to cytomegalovirus in chronically infected women","volume":"203","author":"Sabbaj","year":"2011","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180626074929_CIT0024","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/j.jcv.2009.07.002","article-title":"Development and evidence for efficacy of CMV glycoprotein B vaccine with MF59 adjuvant","volume":"46","author":"Pass","year":"2009","journal-title":"J Clin Virol"},{"key":"key\n\t\t\t\t20180626074929_CIT0025","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/S0140-6736(11)60136-0","article-title":"Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial","volume":"377","author":"Griffiths","year":"2011","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180626074929_CIT0026","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.vaccine.2015.11.056","article-title":"Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: a randomized clinical trial","volume":"34","author":"Bernstein","year":"2016","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20180626074929_CIT0027","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa0804749","article-title":"Vaccine prevention of maternal cytomegalovirus infection","volume":"360","author":"Pass","year":"2009","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180626074929_CIT0028","doi-asserted-by":"crossref","first-page":"e1002172","DOI":"10.1371\/journal.ppat.1002172","article-title":"B cell repertoire analysis identifies new antigenic domains on glycoprotein B of human cytomegalovirus which are target of neutralizing antibodies","volume":"7","author":"P\u00f6tzsch","year":"2011","journal-title":"PLoS Pathog"},{"key":"key\n\t\t\t\t20180626074929_CIT0029","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1128\/JVI.63.5.1995-2001.1989","article-title":"Identification of a neutralizing epitope on glycoprotein gp58 of human cytomegalovirus","volume":"63","author":"Utz","year":"1989","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20180626074929_CIT0030","doi-asserted-by":"crossref","first-page":"5290","DOI":"10.1128\/JVI.66.9.5290-5297.1992","article-title":"A continuous sequence of more than 70 amino acids is essential for antibody binding to the dominant antigenic site of glycoprotein gp58 of human cytomegalovirus","volume":"66","author":"Wagner","year":"1992","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20180626074929_CIT0031","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1099\/0022-1317-73-9-2375","article-title":"Glycoprotein gp116 of human cytomegalovirus contains epitopes for strain-common and strain-specific antibodies","volume":"73","author":"Meyer","year":"1992","journal-title":"J Gen Virol"},{"key":"key\n\t\t\t\t20180626074929_CIT0032","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/jmv.1890390303","article-title":"An ELISA using recombinant proteins for the detection of neutralizing antibodies against human cytomegalovirus","volume":"39","author":"Kropff","year":"1993","journal-title":"J Med Virol"},{"key":"key\n\t\t\t\t20180626074929_CIT0033","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/infdis\/175.3.533","article-title":"The humoral immune response against human cytomegalovirus is characterized by a delayed synthesis of glycoprotein-specific antibodies","volume":"175","author":"Schoppel","year":"1997","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180626074929_CIT0034","doi-asserted-by":"crossref","first-page":"4768","DOI":"10.4049\/jimmunol.174.8.4768","article-title":"Recognition of human cytomegalovirus by human primary immunoglobulins identifies an innate foundation to an adaptive immune response","volume":"174","author":"McLean","year":"2005","journal-title":"J Immunol"},{"key":"key\n\t\t\t\t20180626074929_CIT0035","doi-asserted-by":"crossref","first-page":"8927","DOI":"10.1128\/JVI.00434-13","article-title":"Characterization of a discontinuous neutralizing epitope on glycoprotein B of human cytomegalovirus","volume":"87","author":"Spindler","year":"2013","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20180626074929_CIT0036","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1128\/JVI.02393-14","article-title":"Identification of a neutralizing epitope within antigenic domain 5 of glycoprotein B of human cytomegalovirus","volume":"89","author":"Wiegers","year":"2015","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20180626074929_CIT0037","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.imlet.2007.07.001","article-title":"Location, location, timing: analysis of cytomegalovirus epitopes for neutralizing antibodies","volume":"112","author":"Schrader","year":"2007","journal-title":"Immunol Lett"},{"key":"key\n\t\t\t\t20180626074929_CIT0038","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1099\/0022-1317-71-10-2443","article-title":"The gp116 of the gp58\/116 complex of human cytomegalovirus represents the amino-terminal part of the precursor molecule and contains a neutralizing epitope","volume":"71 (Pt 10)","author":"Meyer","year":"1990","journal-title":"J Gen Virol"},{"key":"key\n\t\t\t\t20180626074929_CIT0039","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1038\/emboj.2008.179","article-title":"Germline V-genes sculpt the binding site of a family of antibodies neutralizing human cytomegalovirus","volume":"27","author":"Thomson","year":"2008","journal-title":"EMBO J"},{"key":"key\n\t\t\t\t20180626074929_CIT0040","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.vaccine.2007.10.048","article-title":"Humoral immunity targeting site I of antigenic domain 2 of glycoprotein B upon immunization with different cytomegalovirus candidate vaccines","volume":"26","author":"Axelsson","year":"2007","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20180626074929_CIT0041","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.molimm.2014.03.015","article-title":"A new look at a poorly immunogenic neutralization epitope on cytomegalovirus glycoprotein B. Is there cause for antigen redesign","volume":"60","author":"Ohlin","year":"2014","journal-title":"Mol Immunol"},{"key":"key\n\t\t\t\t20180626074929_CIT0042","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1006\/viro.2002.1752","article-title":"Binding characteristics determine the neutralizing potential of antibody fragments specific for antigenic domain 2 on glycoprotein B of human cytomegalovirus","volume":"305","author":"Lantto","year":"2003","journal-title":"Virology"},{"key":"key\n\t\t\t\t20180626074929_CIT0043","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1399-3062.2010.00563.x","article-title":"Lack of antibodies against the antigen domain 2 epitope of cytomegalovirus (CMV) glycoprotein B is associated with CMV disease after renal transplantation in recipients having the same glycoprotein H serotypes as their donors","volume":"13","author":"Ishibashi","year":"2011","journal-title":"Transpl Infect Dis"},{"key":"key\n\t\t\t\t20180626074929_CIT0044","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1099\/0022-1317-73-10-2705","article-title":"Neutralizing mechanisms of two human monoclonal antibodies against human cytomegalovirus glycoprotein 130\/55","volume":"73","author":"Ohizumi","year":"1992","journal-title":"J Gen Virol"},{"key":"key\n\t\t\t\t20180626074929_CIT0045","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.1128\/JVI.02687-09","article-title":"Bimolecular complementation defines functional regions of Herpes simplex virus gB that are involved with gH\/gL as a necessary step leading to cell fusion","volume":"84","author":"Atanasiu","year":"2010","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20180626074929_CIT0046","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1099\/0022-1317-80-8-2183","article-title":"Antigenic domain 1 of human cytomegalovirus glycoprotein B induces a multitude of different antibodies which, when combined, results in incomplete virus neutralization","volume":"80 (Pt 8)","author":"Speckner","year":"1999","journal-title":"J Gen Virol"},{"key":"key\n\t\t\t\t20180626074929_CIT0047","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1128\/JVI.79.7.4066-4079.2005","article-title":"Antigenic domain 1 is required for oligomerization of human cytomegalovirus glycoprotein B","volume":"79","author":"Britt","year":"2005","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20180626074929_CIT0048","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1080\/21645515.2016.1164376","article-title":"Preclinical evaluations of peptide-conjugate vaccines targeting the antigenic domain-2 of glycoprotein B of human cytomegalovirus","volume":"12","author":"Finnefrock","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"key\n\t\t\t\t20180626074929_CIT0049","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1128\/AAC.04295-14","article-title":"A high-affinity native human antibody neutralizes human cytomegalovirus infection of diverse cell types","volume":"59","author":"Kauvar","year":"2015","journal-title":"Antimicrob Agents Chemother"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/217\/12\/1907\/25090730\/jiy102.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T17:03:14Z","timestamp":1603904594000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/217\/12\/1907\/4924673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,8]]},"references-count":49,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2018,3,8]]},"published-print":{"date-parts":[[2018,5,25]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiy102","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,6,15]]},"published":{"date-parts":[[2018,3,8]]}}}